Aquestive Therapeutics (NASDAQ:AQST) Rating Lowered to “Sell” at Wall Street Zen

Aquestive Therapeutics (NASDAQ:AQST) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other analysts have also recently issued reports on the company. JMP Securities increased their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a research note on Thursday, October 9th. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Piper Sandler lifted their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average price target of $8.83.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $2.95 on Friday. The company has a market cap of $359.90 million, a P/E ratio of -4.15 and a beta of 1.66. The stock has a 50-day moving average of $5.26 and a two-hundred day moving average of $5.20. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. On average, analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA purchased a new position in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $94,000. Arizona State Retirement System acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $184,000. Arcataur Capital Management LLC purchased a new position in Aquestive Therapeutics in the 4th quarter valued at $239,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Aquestive Therapeutics in the 4th quarter valued at $420,000. Finally, MBM Wealth Consultants LLC acquired a new position in Aquestive Therapeutics in the 4th quarter valued at $109,000. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.